n.moreau

TL2 · Konya

Contributes reviews on supplier material. Based in Konya.

Joined 5 February 2025 · last posted 1d

73 posts, newest first. Showing up to 150.

Tracking a shortage from primary sources rather than rumour — the long version Replied, post #3 · marked as the solution · Access › Shortages · 27 Jul 2026 · 15 likes Regional differences during a shortage are large, and a supply position in one country says nothing about another. Happy to be the one who is wrong here if it settles…
Coming back to: Batch date after test date, and other internal inconsistencies Replied, post #25 · Analytics › COA interpretation · 25 Jul 2026 · 12 likes The fields that make one usable: lot identifier matching the container, test date, method identification specific enough to reproduce, the result as a number, and the…
BPC-157: what the rodent literature actually shows, and what it does not — does this… Replied, post #8 · Compounds › Repair & healing peptides · 20 Jul 2026 · 0 likes TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation…
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #96 · Compounds › Semaglutide · 8 Jul 2026 · 0 likes Post #93 answers the question as asked. The question underneath it is different. Albumin binding is not a unique structural feature and nothing in the class lacks it,…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #26 · Compounds › Retatrutide · 29 Jun 2026 · 0 likes Same experience here, different supplier, so it is at least not unique to one of them.
Revisiting: Journal club: SURMOUNT-1, read without the press release Replied, post #60 · Evidence › Journal club · 24 Jun 2026 · 3 likes Post #59 is the version of this I will quote in future. One addition. Source for the SURMOUNT-1 figure, since it was asked for. It is in the discussion rather than the…
Submitting a sample: the process end to end Replied, post #25 · Sourcing › Independent verification · 19 Jun 2026 · 24 likes How to submit a sample: contact the service directly. They will provide instructions on vial type, quantity, labelling, shipping. Following their instructions exactly…
Bioimpedance and hydration: why the number moves Replied, post #58 · Outcomes › Body composition · 10 Jun 2026 · 4 likes Post #54 put the caveat in the right place and I want to underline it. The most useful protocol is the one you will actually repeat identically. An imperfect…
Racemisation and why it is invisible to a mass measurement Replied, post #15 · Analytics › Impurities & related substances · 9 Jun 2026 · 29 likes Post #13 and I disagree about the size of the effect, not about the direction. Aggregates may be a multiple of the monomer mass and may not elute at all under a…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #32 · Compounds › Repair & healing peptides · 27 May 2026 · 15 likes Post #31 is the version of this I will quote in future. One addition. Stability of BPC-157 in solution: what has been measured in published work covers specific…
Revisiting: Primary endpoint hierarchies and why order matters Replied, post #19 · Evidence › Trials · 10 May 2026 · 3 likes Coming back to post #17, because the follow-up matters more than the original answer. Multiplicity and multiple comparisons: if a trial tests many hypotheses, the…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #44 · Meta › Announcements · 10 May 2026 · 7 likes The moderation log will carry the announcement entry, so the date is recoverable. It will not be visible on the topic itself, which is probably the right level of…
Ultrasound and skinfolds: operator dependence in practice — what changed since Replied, post #38 · Outcomes › Body composition · 23 Apr 2026 · 24 likes Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
CJC-1295 with and without DAC: what the modification does Replied, post #31 · Compounds › Secretagogues & GH axis · 11 Apr 2026 · 0 likes Worth separating two things that post #29 runs together. Adding the boring version of CJC-1295, because the interesting version keeps getting posted and the boring one…
Residual solvents and scavengers: what is looked for — what changed since Replied, post #23 · Analytics › Impurities & related substances · 2 Apr 2026 · 0 likes Coming back to post #20, because the follow-up matters more than the original answer. What I can speak to on Residual solvents and scavengers is narrow, so I will keep…
Preprint servers and what screening they do Replied, post #90 · Evidence › Preprints · 15 Mar 2026 · 3 likes Nothing to add on the substance. Thank you for taking the question at face value.
Which panel is worth repeating and which is worth ignoring — a second dataset Replied, post #78 · Clinical › Bloodwork · 16 Feb 2026 · 0 likes Glycaemic markers integrate over different periods. A point glucose and a longer-term marker disagreeing is not a contradiction; it is two different questions. That is…
Seven-day rolling means and why weekly readings mislead — one year on Replied, post #64 · Outcomes › Progress reports · 16 Feb 2026 · 2 likes A seven-day rolling mean of daily readings has a much smaller standard error and makes most apparent plateaus and sudden drops disappear.
MHRA statements, read directly Replied, post #78 · Regional › UK & Ireland · 29 Jan 2026 · 6 likes A request rather than an answer: could whoever has the primary source for MHRA statements post it? I have seen the claim three times this month and each version had…
Request: export my own posts — one year on Replied, post #36 · Meta › Feature requests · 20 Jan 2026 · 16 likes Post #32 put the caveat in the right place and I want to underline it. Small request: let me filter Latest by whether I have read the topic. Unread exists as a tab and…
Designing a personal experiment that could change your mind — one year on Replied, post #2 · Research Methods › N-of-1 designs · 12 Jan 2026 · 21 likes Write down what you would accept as evidence that it did not work, before starting. That one sentence turns an anecdote into an experiment. That is the practical…
Injection discomfort: needle gauge, volume, temperature, technique Replied, post #14 · Practice › Administration · 12 Jan 2026 · 9 likes Bleeding at the injection site: normal and usually minimal. A little blood at the needle site after withdrawal is not a reason to assume you lost a significant dose.…
Distinguishing expected GI effects from something that needs urgent attention Replied, post #81 · Practice › Side effects · 12 Jan 2026 · 0 likes Effects that improve with time and effects that improve with dose reduction are different findings. Working out which you have requires holding the dose steady long…
IGF-1 as a surrogate endpoint and its limitations Replied, post #6 · Compounds › Secretagogues & GH axis · 8 Jan 2026 · 22 likes That is clearer than the version I had in my head. Thank you.
Tracking that stops updating and then resumes — the long version Replied, post #53 · Sourcing › Logistics · 18 Dec 2025 · 12 likes Anyone deciding whether a delay is a problem should ask what would change if they waited another week. Usually the answer is nothing. For what it is worth, the same…
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version Replied, post #69 · Clinical › Special populations · 18 Dec 2025 · 21 likes I would be cautious about generalising from the Older adults example above. It is a good example. It is one example.
Coming back to: Feature request: should a dose-equivalence tool exist at all? Replied, post #17 · Data & Tools › Calculators · 24 Nov 2025 · 0 likes Two sentences on Feature request and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow. What is…
Retatrutide's phase 2 heart-rate signal and how to think about it Replied, post #15 · Compounds › Retatrutide · 23 Nov 2025 · 0 likes Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase 2 trial without a dual-agonist comparator arm…
The anatomy of a question that gets answered within an hour — the long version Replied, post #133 · Start Here › How to Ask · 23 Nov 2025 · 0 likes It is fine to say you cannot explain why you are asking. Nobody will press, and the technical part of the question can usually be answered without the context. I am…
Revisiting: GLP-1 receptor distribution: central and peripheral Replied, post #63 · Pharmacology › Receptor biology · 7 Nov 2025 · 20 likes Everything in post #60 holds. The case it does not cover is the one I have. Receptor distribution explains the side-effect profile better than anything else. GLP-1…
Dead volume across syringe and needle combinations Replied, post #19 · Devices › Syringes & needles · 3 Nov 2025 · 27 likes Reusing a needle blunts it and there is no benefit to offset that. The second injection with the same needle is the one people describe as painful. This is the version…
Oral versus injectable exposure: comparing apples to a different fruit Replied, post #5 · Compounds › Oral incretins · 1 Nov 2025 · 18 likes Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as…
A preprint whose numbers changed substantially at publication Replied, post #69 · Evidence › Preprints · 27 Sep 2025 · 3 likes Do not build anything on a preprint that you would mind rebuilding: if the preprint later changes substantially in revision or shows different results when published,…
Revisiting: Reading a denial letter as a specification for your appeal Replied, post #125 · Access › Insurance & coverage · 18 Sep 2025 · 0 likes Reading back through the Reading a denial letter threads from last year, the same three questions come up every time and only one of them has ever been answered…
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #117 · Data & Tools › Calculators · 15 Sep 2025 · 1 like Titration planner refuses has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Coming back to: Where the integrator drew the baseline, and how much it moved the number Replied, post #2 · Analytics › HPLC & UHPLC · 14 Sep 2025 · 0 likes Where I part company with the opening post, and it is a narrow parting. Where the baseline is drawn is the least documented and most consequential choice in the whole…
Power cut for eleven hours: how I assessed it afterwards Replied, post #37 · Practice › Storage & stability · 28 Aug 2025 · 0 likes Post #35 and I disagree about the size of the effect, not about the direction. Clarity is a weak test. A solution can lose a significant fraction of its active content…
Why "any advice?" is the least effective ending for a post — the long version Replied, post #39 · Start Here › How to Ask · 15 Aug 2025 · 0 likes Lab result questions: state the result, the reference interval, and what else is on the same panel. A single flag on a single draw is usually uninformative without…
Meeting a protein target on a suppressed appetite Replied, post #15 · Nutrition & Training › Protein & intake · 13 Aug 2025 · 11 likes Meeting protein targets on suppressed appetite: this is where the practical difficulty lies. Eating more protein when appetite is suppressed is genuinely hard.…
The "under review" status pill and when a moderator applies it — a second dataset Replied, post #8 · Evidence › Preprints · 12 Aug 2025 · 1 like Picking up post #5: that is the part I would want checked first. A preprint with the data and code attached is frequently more checkable than a published paper without…
How to research a compound with no human data without deceiving yourself Replied, post #109 · Compounds › Other compounds · 4 Aug 2025 · 1 like Coming back to post #107, because the follow-up matters more than the original answer. When "no data" is the complete and final answer: if there is no published human…
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #2 · Compounds › Cagrilintide & amylin analogues · 16 Jul 2025 · 19 likes A methods point on Amylin analogue mechanism rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference…
Lipase elevation without symptoms: the interpretation problem Replied, post #3 · Clinical › Bloodwork · 11 Jul 2025 · 1 like Thank you — that answers what I came here to find out.
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #131 · Compounds › Tirzepatide · 8 Jul 2025 · 0 likes Post #129 and I disagree about the size of the effect, not about the direction. The practical version of tirzepatide in type 2 diabetes is three sentences long. The…
Repeatability versus intermediate precision Replied, post #127 · Analytics › Method validation · 3 Jul 2025 · 7 likes Precision has two levels worth distinguishing: repeatability within a run and intermediate precision across days, analysts and instruments. The second is where most…
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #43 · Compounds › Semaglutide · 26 Jun 2025 · 9 likes Post #39 describes the usual case. This is about the unusual one. Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the…
Repeatability versus intermediate precision Replied, post #38 · Analytics › Method validation · 22 Jun 2025 · 0 likes The limit of quantitation determines what the impurity table can honestly contain. Peaks below it can be reported as detected and cannot be reported as a number.…
Half-life, steady state, and accumulation worked through Replied, post #128 · Pharmacology › Pharmacokinetics · 16 Jun 2025 · 4 likes Steady state is approached in roughly four to five half-lives. For a compound with a week-long half-life that is four to five weeks, which is where the escalation…
A report I filed that turned out to be wrong, and the correction Replied, post #54 · Sourcing › Vendor reports · 15 May 2025 · 17 likes A difference inside method repeatability is not a disagreement. Saying so in your own report prevents somebody else reading it as one. Adding this to the thread rather…
A claim built entirely on a subgroup analysis Replied, post #26 · Evidence › Study critique · 9 May 2025 · 3 likes Per-protocol and intention-to-treat analyses answer different questions and neither is the honest one by default. Reporting both is the practice worth insisting on.
Which panel is worth repeating and which is worth ignoring Replied, post #14 · Clinical › Bloodwork · 6 May 2025 · 2 likes Adding what did not work for me on panel, since the failures never get written up and they are half the useful information.
Reading a chromatogram someone posted without axes Replied, post #29 · Analytics › HPLC & UHPLC · 5 May 2025 · 12 likes Before anything else: what was the gradient, and at what wavelength? Area percent at different wavelengths is not the same number even on the same sample because…
HbA1c lag and what it can and cannot tell you at eight weeks Replied, post #13 · Clinical › Bloodwork · 16 Apr 2025 · 21 likes That is the distinction I keep failing to hold on to. Written down now.
Holding a dose indefinitely: is there a documented downside? Replied, post #16 · Practice › Dosing & titration · 5 Apr 2025 · 0 likes Confirming post #13 from a second method, which matters more than confirming it from a second person. Escalating before steady state means you are judging a dose you…
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence Replied, post #35 · Compounds › Secretagogues & GH axis · 2 Apr 2025 · 0 likes Tesamorelin has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Why cagrilintide alone is discussed so much less than in combination Replied, post #41 · Compounds › Cagrilintide & amylin analogues · 27 Mar 2025 · 3 likes Worth separating two things that post #39 runs together. Worth distinguishing the combination product from the two components bought separately and mixed. Those are…
A page that has drifted out of date and needs a maintainer Replied, post #77 · Documentation › Wiki requests · 17 Mar 2025 · 3 likes No notes. Posting so the count is not one.
Retatrutide dose escalation in the published trials Replied, post #20 · Compounds › Retatrutide · 17 Mar 2025 · 0 likes Adding what did not work for me on retatrutide dose escalation, since the failures never get written up and they are half the useful information.
One lot is one lot: when a report becomes a pattern — the long version Replied, post #59 · Sourcing › Vendor reports · 16 Mar 2025 · 1 like Comparing your result to somebody else's on a different lot is not a comparison of suppliers. Lot is the unit and it should be in every report.
Distinguishing a deletion sequence by mass alone Replied, post #5 · marked as the solution · Analytics › Mass spectrometry · 20 Jan 2025 · 10 likes Tandem mass spectrometry: MS/MS fragments the molecular ion and uses fragment masses to confirm identity and detect modifications. A simple identity confirmation by…
Follow-up: Individual participant data versus aggregate data Replied, post #85 · Evidence › Meta-analyses · 11 Jan 2025 · 30 likes Post #81 and I disagree about the size of the effect, not about the direction. Individual participant data versus aggregate is one of those subjects where the general…
What changed in 2026, by region Replied, post #18 · Access › International · 11 Dec 2024 · 11 likes Post #17 answers the question as asked. The question underneath it is different. Nothing here is legal advice, and in this subcategory that caveat is doing real work…
Revisiting: Moderation log format change Replied, post #53 · Meta › Announcements · 4 Dec 2024 · 1 like Two questions I would want answered before drawing anything from the Moderation log format change data above: how were the cases selected, and what happened to the ones…
Type 1 diabetes: off-label use and the evidence gap — what changed since Replied, post #33 · Clinical › Special populations · 22 Nov 2024 · 0 likes Type 1 diabetes: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Coming back to: Research-use-only labelling: what it means and what it does not Replied, post #34 · Sourcing › Regulatory · 20 Nov 2024 · 24 likes Worth separating two things that post #32 runs together. Filing a mild objection to the consensus on Research-use-only labelling. Mild because I might be wrong; an…
EMA product information as a primary source — does this still hold? Replied, post #38 · Regional › European Union · 15 Nov 2024 · 1 like Post #36 describes the usual case. This is about the unusual one. Language versions of the product information are all official and occasionally differ in emphasis.…
Why "any advice?" is the least effective ending for a post Replied, post #38 · Start Here › How to Ask · 15 Nov 2024 · 0 likes The specific question in the title is more useful than you might think. A title like "a question I have" forces the person answering to guess what you want to know. A…
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #100 · Compounds › Other compounds · 7 Nov 2024 · 12 likes I have no financial interest in anything named in this thread and I want to say so before I comment on Melanocortin agonists, because it is the sort of subject where it…
About the International category Replied, post #9 · Access › International · 9 Oct 2024 · 16 likes A regional experience posted here should say which year it describes. The archive keeps these permanently and they age faster than anything else on the site.
Progressive overload when the scale is falling — one year on Replied, post #114 · Nutrition & Training › Resistance training · 2 Oct 2024 · 16 likes Having read the whole Progressive overload thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a…
Reporting a discrepancy without making an allegation Replied, post #61 · Sourcing › Vendor reports · 7 Sep 2024 · 0 likes An honest declaration on reporting a discrepancy: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding…
Follow-up: A partial dose because the pen emptied mid-injection Replied, post #15 · Practice › Administration · 25 Aug 2024 · 17 likes If you have to inject at a different time of day than usual, that is a much smaller perturbation than it feels for a weekly compound with a week-long half-life.
Blind submission and why it changes minds Replied, post #11 · Sourcing › Independent verification · 8 Jul 2024 · 10 likes Building on post #8 rather than restating it. What I would want before treating blind submission as settled: the method, the sample, and whether anyone tried to find…